Trials / Completed
CompletedNCT01613690
Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
An Open Label, Non-randomized, Parallel-group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of a Single Dose of NVA237 in Subjects With Mild, Moderate, Severe and End-stage Renal Impairment With That in Matched Healthy Control Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to see how the body processes and gets rid of NVA237 in people who have impaired kidney function compared to people whose kidney function is normal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NVA237 | NVA237 is administered via a BREEZHALER device |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2012-06-07
- Last updated
- 2020-12-19
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT01613690. Inclusion in this directory is not an endorsement.